- Details
- Yann Vano joins Pedro Barata to discuss the overall survival and efficacy results from the randomized phase II BIONIKK trial of second-line treatment for patients with metastatic clear cell renal cell carcinoma (mRCC). The trial included patients with ccrc1-4 tumors and randomized them to receive nivo, nivo-ipi, or VEGFR-TKI. In the 18-month follow-up the study showed that nivo-based therapies wer...
|
- Details
- Thomas Hope joins Phillip Koo to discuss real-world challenges associated with patient selection, laboratory abnormalities, and workflow issues in treating patients with lutetium-177 PSMA in a high-volume care center. He also talks about the need to identify when to stop therapy and how to spread out doses effectively while minimizing toxicity. Additionally, Dr. Hope highlights the importance of p...
|
- Details
- Lisa Gudenkauf joins Phillip Koo to discuss her work on developing a patient-reported outcome measure (PRO) called FACT-RNT that targets symptoms and toxicities specific to radionuclide therapy. She notes that dry mouth is a significant issue, but other symptoms that may be missed that aren't being assessed quite as much are things like feeling isolated from your family after you've had treatment....
|
- Details
- Jones Nauseef speaks with Alicia Morgans about a trial in progress dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA. With the approval of Lutetium 177 Jones Nauseef explains that the study team decided to modify the study design to include a post-177-Lu-PSMA cohort because patie...
|
- Details
- Jones Nauseef joins Alicia Morgans to discuss a navigable interface for whole genome and transcriptome sequencing to identify additional targets in castration-resistant prostate cancer and neuroendocrine prostate cancer. This platform aims to help clinicians understand genetic information and how to incorporate it into their clinical decision-making for patients. Biographies: Jones T. Nauseef, MD,...
|
- Details
- Pedro Barata and Mauricio Burotto discuss the 3-year follow-up of the CheckMate-9ER study. This study compares the combination of nivolumab plus cabozantinib with sunitinib for first-line treatment of advanced renal cell carcinoma (RCC). Nivolumab plus cabozantinib maintained survival and response benefits after 3 years of follow-up. Median overall survival with nivolumab plus cabozantinib improve...
|
- Details
- Laurence Albiges joins Pedro Barata to discuss the CaboPoint study, a clinical trial designed to examine the question of activity and safety of cabozantinib single agent in patients who failed first-line combination therapy for advanced renal cell carcinoma (aRCC). The study has two subgroups - Cohort A and Cohort B. Cohort A is the activity of cabozantinib after nivolumab/pembrolizumab, and Cohor...
|
- Details
- Bradley McGregor joins Pedro Barata in a conversation to discuss the results of the COSMIC-021 study, which looked at the combination of cabozantinib with atezolizumab for non-clear-cell, renal cell carcinoma. The study showed clinical activity for the combination of cabozantinib and atezolizumab across the 32 patients with variant-histology renal cell carcinoma, with no new toxicity signals. The...
|
- Details
- Rahul Aggarwal joins Alica Morgans in conversation discussing a phase II study of patients with de novo small cell neuroendocrine prostate cancer, a high-risk group of patients with limited standard of care treatment options. The treatment was a combination immunotherapy trial, combining pembrolizumab, an immune checkpoint inhibitor, with BXCL 701, an investigational agent. The composite response...
|
- Details
- FORMULA-509 (NCT03141671) is an investigator-initiated, multi-center, open-label, randomized trial. Patients had to have a PSA≥0.1 ng/mL post-radical prostatectomy and one or more unfavorable features (Gleason 8-10 disease, PSA> 0.5 ng/mL, pT3/T4, pN1 or radiographic N1, PSA doubling time 0.5 ng/mL at baseline and should be considered a treatment option for patients at high risk who meet that crit...
|
